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This study was carried out to understand the influence of a selected antiarrhythmic drug on the 
pharmacodynamics and pharmacokinetics of an antidiabetic drug in animal models. Pharmacodynamic 
and pharmacokinetic responses were determined by measurements of blood glucose and serum insulin 
and serum metformin to drug interactions between disopyramide and metformin. Single dose and multi 
dose studies showed that the maximum blood glucose reductions in normal and diabetic rats were at the 
6th hour, and in rabbits at the 3rd hour. Glucose-insulin homeostasis was evaluated to assess the safety and 
effectiveness of the combination. There was a marginal increase in the pharmacokinetic parameters of 
metformin with multiple dose treatments of disopyramide but no significant changes in kinetic parameters 
between single and multiple dose studies, compared to metformine alone. There may be a possibility of 
disopyramide and metformin interaction at the excretion stage, or an additive pharmacodynamic action. 
This study validates the drug interaction in two dissimilar species, which indicates more probability of 
its occurrence in humans.
Keywords: Disopyramide/pharmacokinetic interactions/pharmacodynamic. Metformin/ pharmacokinetic 
interactions/pharmacodynamic. Drug Interactions. Hypoglycaemia. Diabetes mellitus.
INTRODUCTION
Drug interactions are more serious with high risk 
disorders such as diabetes, hypertension, or cardiac 
abnormalities, or when using high risk drugs including 
antidiabetic and antihypertensive drugs, drugs used in 
congestive heart failure and antiasthmatic drugs. High risk 
disorders and the use of high risk drugs implies they should 
be observed closely and carefully. Diabetes mellitus is one 
such disorder, which requires vigilant management of its 
therapy with respect to blood glucose levels, since both 
hyperglycemia and hypoglycemia are undesirable.
At present, the number of patients suffering 
from diabetes and its associated comorbidities of 
atherosclerosis, dyslipidemia and other cardiac disorders, 
is increasing worldwide. Diabetes mellitus is a chronic 
metabolic disorder characterized by a rise in blood 
glucose level called hyperglycemia. It is of two types, 
type 1 accounting for 5% prevalence and type 2 for 95% 
prevalence among diabetics. The increasing prevalence 
of type 2 diabetes may confer 75-90% of the excess 
risk of diabetic retinopathy, neuropathy, nephropathy 
and macrovascular complications including coronary 
artery disease, diabetic dyslipidemia, hypertension, 
oxidative stress, cardiac myopathy, hyperinsulinemia, 
cerebrovascular disease and peripheral vascular disease. 
(Vinik, Flemmer 2002; Tenenbaum et al., 2004).
According to the World Health Organization (WHO, 
2009,), 40-60% of type 2 diabetics are obese, and have an 
increased likelihood of developing coronary artery disease 
(CAD) and other atherosclerotic manifestations. The 
prevalence of CAD was 21.4% among diabetics, compared 
to 9.1% in those with normal glucose tolerance (Mohan 
et al., 2001). In such a situation, there may be chances 
for interactions between antidiabetic and antiarrhythmic 
drugs, which may be beneficial or harmful. Consequently, 
there is a need to monitor drug therapy in polypharmacy in 
order to gain a better therapeutic effect with a lower rate 
of risk. Drug interactions may be of a pharmacokinetic or 
pharmacodynamic nature.
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It is now known that millions of patients take 
conventional medicines concomitantly, often without 
the knowledge of their physicians. Considering our 
present lack of understanding of drug interactions, proper 
reporting of such cases, careful vigilance, evidence 
based appraisals and constantly updated reviews of such 
information are very important to promote understanding 
of this area.
Biguanides are the drugs of choice for the treatment 
of type 2 diabetes. Metformin is a widely used biguanide. 
Antiarrhythmic drugs, such as sodium channel blockers, 
are widely used for the treatment of arrhythmias; among 
the sodium channel blockers, disopyramide is widely 
used. Disopyramide is metabolized by P450 CYP 3A4 
isoenzyme in the liver (Norpace(R), 1995).
Metformin is not metabolised (Pentikainen, 
Koivula, Hiltunen, 1982; Glumetza(TM), 2006). It is 
excreted unchanged in the urine and does not undergo 
hepatic metabolism (no metabolites have been identified 
in humans) or biliary excretion (Glucophage(R), 2001). 
Tubular secretion is the major mechanism responsible 
for the elimination of metformin (Glumetza(TM), 2006). 
Since disopyramide, a sodium channel blocker used as an 
antiarrhythmic drug, is known to produce hypoglycemia 
due to insulin release, it may augment metformin activity 
by a combined pharmacodynamic mechanism. Whether 
it also interferes with the pharmacokinetics of metformin 
is not known, so it is necessary to establish the safety of 
this combination.
The present study was undertaken to understand the 
influence of a selected antiarrhythmic drug (disopyramide) on 
the pharmacodynamics of an antidiabetic drug (metformin) 
in normal and diabetic rats, and the pharmacodynamics and 
pharmacokinetics in normal rabbits. This study is planned 
to establish the safety of the drug combination in two 
dissimilar species of animal models, namely rats and rabbits, 
with respect to blood glucose level and serum insulin, and to 
establish the mechanisms responsible for the interactions, if 
any. The outcome of the work provides information which 
has clinical utility.
MATERIAL AND METHODS
A sample of metformin (100g) was obtained from 
Dr. Reddys Laboratories, Hyderabad, India; and a sample 
of disopyramide (10g) was obtained from RPG Life 
Sciences Ltd., Mumbai. Also obtained were acetonitrile 
(HPLC grade) manufactured by Qualigens Chemicals, 
Mumbai, India, potassium dihydrogen phosphate (AR 
Grade), and orthophosphoric acid, both manufactured by 
Fine Chemicals, Mumbai, India. Triple distilled water was 
prepared in the laboratory. Blood glucose kits (Auto span) 
manufactured by Span Diagnostics Ltd, Surat, India, were 
purchased from a local community pharmacy. A standard 
animal pellet diet was used, manufactured by Rayan 
Biotechnologies Pvt. Ltd, Hyderabad, India.
Inbred adult albino rabbits and albino rats (Wistar 
strain) of both genders were purchased from Sainath 
Agencies, Hyderabad, India. They were maintained under 
standard laboratory conditions at an ambient temperature of 
25 ± 2 °C and 50 ± 15% relative humidity with a 12 h light 
and 12 h dark cycle. They were fed with the commercial 
pellet diet and water ad libitum. The experimental protocol 
was approved by the Institutional Animal Ethics Committee 
(IAEC/SUCP/05/2010]. Rats were fasted for 18 h prior 
to the experiment, allowing access to water. During the 
experiment, food and water were withdrawn.
Pharmacokinetic and pharmacodynamic responses 
were determined related to the selected drug disopyramide 
given alone, and in combination with the antidiabetic drug, 
metformin. The results were compared using the unpaired 
Student’s t-test to determine statistical significance. 
Estimation of metformin from rabbit serum by 
HPLC
An isocratic high performance liquid chromatography 
(HPLC) was used, equipped with automated waters, 2695 
pump model, variable wavelength programmable DAD or 
UV detector no: 2487, Symmetry C18 (4.6 x 150mm, 5 
µm, Make: XTerra) or equivalent, particle size 5µm. The 
HPLC system was equipped with the software Empower 
2 (Waters).
The mobile phase consisted of a phosphate buffer 
and acetonitrile (HPLC grade; Qualigens, Mumbai, 
India). The mobile phase components were filtered before 
use through a 0.45m membrane filter and pumped in 
the ratio of 35:65 pH3, adjusted with orthophosphoric 
acid (phosphate buffer: acetonitrile from the respective 
solvent reservoirs). The flow rate of the mobile phase was 
maintained at 0.8 mL/min and the column temperature 
was maintained at 40 oC. The eluent was monitored at 
240 nm wavelength with the DAD or UV detector on the 
C-18 column.
Plasma sample treatment
To 0.5 mL of serum in a 1.5 mL Eppendrof tube, 
0.5 mL acetonitrile was added to precipitate proteins and 
extract metformin. The Eppendrof tubes were vortex-
mixed for 5 min to bring about the complete extraction 
of metformin from the proteins and, after standing for 10 
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min, the tubes were centrifuged at 5000 rpm for 10 min. 
The upper layer (about 100 µL) was separated with the 
help of a syringe and filtered through 0.45 µm, 13 mm 
nylon membrane filters (Pall Life Sciences, Mumbai, 
India). About 20 µL of filtrate was injected in the HPLC 
system. The eluent was detected by UV detector at 240 nm, 
and the data were acquired, stored and analyzed with the 
software Empower 2 (Waters). Calibration samples were 
prepared by spiking 200 µL of the individual blank serum 
with the appropriate amount of drug on the day of analysis. 
Samples for the determination of recovery, precision and 
accuracy were prepared by spiking the control rabbit 
serum in bulk of appropriate concentrations (50, 100, 200, 
500 and 1000 ng/mL) and stored at -4 oC.
Normal rats
The normal albino rats of either sex were divided 
into four groups of six each. All the rats weighing between 
165 to 250 g were given different drugs orally, as follows:
Group I: disopyramide 3.6 mg/200 g body weight.
Group II: metformin (2TD) 2 X Therapeutic Dose 18 
mg/200 g body weight.
Group III: disopyramide 3.6 mg/200 g body weight and 
then after 30 min metformin 18 mg/200 g body weight.
Group IV: disopyramide for 7 days with regular feeding, 
later after 18 h of fast they were again given the combined 
dose (disopyramide + metformin) on the 8th day.
Diabetic rats
Induction of diabetes
Albino rats of either sex were used for the induction 
of diabetes. These animals were injected with a freshly 
prepared aqueous solution of alloxan monohydrate in 
two doses of 100 mg/kg and 50 mg/kg body weight 
intraperitoneally for two consecutive days. Then 10% 
dextrose was administered to combat the immediate 
hypoglycemia. Blood sugar was measured and rats 
showing fasting blood sugar levels above 250 mg/dL were 
selected for the study.
The diabetic rats were divided into four groups of 
six each. All the rats, weighing between 165 to 250 g, were 
given different drugs orally, as follows:
Group I: disopyramide 3.6 mg/200g body weight.
Group II: metformin 2TD 18 mg/200g body weight.
Group III: disopyramide 3.6 mg/200 g body weight and 
then after 30 min, metformin 18 mg/200g body weight.
Group IV: disopyramide for the 7 days with regular feeding; 
later, after 18 h of fast, they were given the combined dose 
(disopyramide + metformin) on the 8th day.
Blood samples, drawn from a retro orbital puncture, 
were estimated for blood glucose from all the above 
groups of normal and diabetic rats. The blood samples 
were collected at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h intervals 
from all the groups of rats after drug administration and 
were subjected to estimation of blood glucose by the 
GOD/POD method; serum insulin was estimated by 
radioimmunoassay; and the insulin resistance index and 
β-cell function were determined by homeostasis model 
assessment. All the drugs were administered orally.
Rabbits
A group of six rabbits was given metformin 2TD 
70 mg/1.5kg body weight, followed by a one week 
period of washout, then the same group of rabbits was 
given disopyramide 14 mg/1.5kg body weight. Later on 
washout period for one week, then same group was given 
disopyramide 14 mg/1.5kg, orally 30 mins prior to the 
administration of metformin (2TD) 70 mg/1.5kg body 
weight.
Then, after the one week washout period, a similar 
group of rabbits were given disopyramide 14mg/1.5kg body 
weight for 7 days continuously; on the 8th day, disopyramide 
14mg/1.5kg body weight was given orally 30 mins prior to 
the administration of metformin (2TD) 70mg/1.5kg. Blood 
samples were withdrawn at 0, 1, 2, 3, 4, 6, 8, 12, 16, 20 and 
24 h intervals from a marginal ear vein puncture and were 
analyzed for blood glucose by the GOD/POD method; 
serum insulin was estimated by radioimmunoassay in a fully 
automated 12 well multi gamma counter radioimmunoassay 
system using 125I (PC RIA MAS, Stratee, Germany); and the 
insulin resistance index and β-cell function were determined 
by homeostasis model assessment.
HOMA-2: the updated HOMA computer model, 
that estimates the insulin resistance index, β-cell function 
and insulin sensitivity, was obtained from the program 
HOMA calculator v 2.2.3 (Oxford Centre for Diabetes 
Endocrinology and Metabolism, 2009).
The results were expressed as micro international 
units/mL (µIU/mL) for serum insulin and serum metformin, 
estimated by the HPLC method. The pharmacokinetic 
parameters were calculated from the blood metformin data 
using the kinetic software RAMKIN.
RESULTS AND DISCUSSION
Chromatography
The cal ibrat ion curve was l inear  over  the 
concentration range of 300ng/mL to 2000ng/mL. The 
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limit of quantification (LOQ) was estimated to be 300ng/
mL by analyzing the drug at low concentrations of the 
calibration curves. To establish the limit of determination 
(LOD), lesser plasma concentrations than the LOQ were 
used; the LOD was found to be about 15 ng/mL (signal-
to-noise ratio of 3) shown in Figures 1 and 2.
Accuracy and precision
For the purpose of determining the intraday and 
interday accuracy and precision, the concentration of 
metformin used in five replicates of plasma spiked with 
300, 600, 900, 1200 and 1500 ng/mL metformin was 
estimated by HPLC within a day, or on different days. The 
values were found within the limits (<15%) specified for 
inter and intraday precision.
Recovery
The recovery of metformin from plasma was 
estimated at 300, 600, 900, 1200 and 1500 ng/mL 
concentrations by comparing the peak areas of the spiked 
plasma standards with those of the corresponding plain 
standards containing the corresponding concentration in 
the mobile phase that represented recovery was 99.32 %, 
100.81%, 98.77%, 98.99% and 100.67%.
Normal rats
Disopyramide induced hypoglycemia was studied 
by administering doses TD 3.6 mg/200 g bodyweight. 
Disopyramide produced a peak blood glucose reduction 
of 35.94 ± 06.70% at 6 h, and serum insulin levels were 
10.55 ± 3.78 µU/mL at 6 h.
Metformin 2TD (18mg/200g body weight) 
produced 31.30 ± 03.50 % peak reduction at 6 h and the 
serum insulin level was 11.82 ± 1.56 µU/mL at 6 h. In 
the disopyramide combination, metformin produced a 
peak reduction of 43.09 ± 02.40% at 6 h and the serum 
insulin level was 12.84 ± 3.67 µU/mL at 6 h. Compared to 
the metformin control, the combination with metformin 
enhanced the percentage of blood glucose reduction and 
insulin level.
The multiple dose of disopyramide and metformin 
produced a peak blood glucose reduction of 45.93 ± 
03.56% at 6 h and the serum insulin level was 15.20 ± 
6.98 µU/mL. Compared to the individual drug and single 
dose drug combination, the multiple dose combination 
with metformin enhanced glucose reduction, as shown in 
Tables I and II, and Figure 3.
Diabetic rats
Metformin, 2TD (18 mg/200 g body weight) 
produced a reduction in blood glucose with a peak activity 
of 40.22 ± 01.58 % at 6 h and a serum insulin level of 10.84 
± 6.7 µU/mL at 6 h. Disopyramide induced hypoglycemia 
was studied by administering doses TD 3.6 mg/200 g 
bodyweight. It reduced blood glucose with 39.20 ± 01.90% 
as peak activity at 6 h and the serum insulin level was 
10.56 ± 2.1 µU/mL at 6 h.
The disopyramide single dose with metformin 
combination produced a peak reduction of blood glucose 
47.23 ± 01.99% at 6 h and the serum insulin level was 
11.89 ± 9.2 µU/mL at 6 h. Compared to the metformin 
matched control, the combination with metformin 
enhanced the glucose reduction.
The multiple dose combination of disopyramide 
with metformin produced a peak blood glucose reduction 
of 49.04 ± 02.81% at 6 h and the serum insulin level was 
12.13 ± 9.3 µU/mL at 6 h. Compared to the individual drug 
and single dose combination, multiple dose combination 
FIGURE 1 - Standard graph of metformin in serum.
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with metformin enhanced the glucose reduction and serum 
insulin levels, as shown in Tables II and III.
Normal rabbits
Metformin 2TD (70mg/1.5kg body weight ) 
produced a reduction in blood glucose level with a peak 
activity of 31.09 ± 01.54% at the 3rd h, and a maximum 
serum metformin concentration was found of 1184 ± 35.70 
ng/mL at the 3rd h. The serum insulin was found to be 
10.84 ± 3.45 µ U/mL at the 3rd h with metformin treatment 
in normal rabbits.
In the single dose study of disopyramide with 
metformin, the maximum reduction in blood glucose, 
that is, 41.14 ± 03.18% at the 3rd h was observed, and an 
increase in serum insulin level of 15.87±1.51 µU/mL at 
the 3rd h with disopyramide and also a slight increase in 
peak serum metformin concentration of 1209 ± 17.62 ng/
mL at the 3rd h in normal rabbits.
In the multiple dose study of disopyramide with 
FIGURE 2 - Typical chromatogram of metformin.
TABLE I - Percentage blood glucose reduction after oral administration of metformin 18 mg/200 g body weight, disopyramide 
3.6 mg/200 g body weight, disopyramide single dose study and multiple dose study in normal rats (n=6)
Time (h)
Mean percentage blood glucose reduction ± SD
Metformin Disopyramide Single dose combination Multiple dose combination
1 11.35 ± 00.97 22.98 ± 05.38 14.51 ± 01.48 14.86 ± 01.94
2 19.11 ± 04.08 32.30 ± 06.12 23.08 ± 01.81 25.76 ± 01.67
3 23.42 ± 03.49 32.14 ± 07.10  33.46 ± 01.19** 34.92 ± 02.13**
4 28.26 ± 04.60 28.75 ± 05.87 41.24 ± 01.90*** 44.78 ± 03.45***
6 31.30 ± 03.50 35.94 ± 06.70 43.09 ± 02.40*** 45.93 ± 03.56***
8 24.37 ± 02.60 18.70 ± 01.46 35.19 ± 02.07 38.51 ± 03.49
10 18.24 ± 04.57 10.60 ± 02.42 25.14 ± 02.99 29.22 ± 03.91
12 11.94 ± 04.26 05.41 ± 00.82 15.28 ± 01.45 16.46 ± 02.95*
*** Significant at P<0.001; ** Significant at P< 0.01; *Significant at P<0.05 compared to control metformin 2TD.
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metformin, the maximum reduction in blood glucose of 
43.11 ± 03.52 % was noted at the 3rd h, and the serum 
insulin of 18.76±7.58 µU/mL at the 3rd h. The peak 
serum metformin concentration was 1219 ± 17.33 ng/mL 
at the 3rd h in normal rabbits, as described in Tables IV, 
V and VI.
The etiology of diabetes involves several factors; 
and it is considered as an autoimmune disorder (Castano, 
TABLE II - Percentage blood glucose reduction after oral administration of metformin 18 mg/200 g body weight, disopyramide 
3.6 mg/200g body weight, disopyramide single dose study and multiple dose study in diabetic rats (n=6)
Time (h)
Mean percentage blood glucose reduction ± SD
Metformin Disopyramide Single dose combination Multiple dose combination
1 12.83 ± 01.19 22.90 ± 01.13 14.81 ± 01.30 14.37 ± 01.30
2 24.72 ± 03.52 30.30 ± 03.15 24.75 ± 02.05 27.14 ± 01.30
3 31.98 ± 03.53 30.90 ± 02.70 35.40 ± 02.33 35.77 ± 01.16
4 37.16 ± 02.11 31.50 ± 04.90 44.74 ± 02.02 47.42 ± 03.11
6 40.22 ± 01.58 39.20 ± 01.90 47.23 ± 01.99*** 49.04 ± 02.81***
8 29.81 ± 01.66 18.41 ± 00.70 42.44 ± 01.50** 43.76 ± 02.66**
10 21.72 ± 05.03 13.10 ± 01.60 28.39 ± 03.27* 29.12 ± 01.63**
12 14.33 ± 02.48 06.27 ± 01.00 15.47 ± 02.52 15.85 ± 01.05
*** Significant at P<0.001; ** Significant at P< 0.01; *Significant at P<0.05 compared to control metformin 2TD.
TABLE III - Effect of disopyramide on the activity of metformin in normal rats and diabetic rats (N=6)
Parameter
Metformin Disopyramide
Disopyramide + metformin 
(SDA)
Disopyramide + metformin 
(MDA)
3rd h 6th h 12th h 3rd h 6th h 12th h 3rd h 6th h 12th h 3rd h 6th h 12th h
Normal rats
Glucose (m g/dL)
62.83 ± 
04.50
56.33 ± 
02.10
72.16 ± 
02.13
64.50 ± 
06.60
60.83 ± 
05.30
90.00 ± 
04.33
60.16 ± 
02.63
51.50 ± 
03.70
76.66 ± 
04.45
57.16 ± 
05.11
47.66 ± 
06.80
73.50 ± 
07.91
Insulin (µU/mL)
10.25 ± 
2.32
11.82 ± 
1.56
09.35 ± 
1.78
09.85 ± 
5.45
10.55 ± 
3.78
07.12 ± 
1.74
10.95 ± 
4.89
12.84 ± 
3.67
08.75 ± 
3.98
11.54 ± 
2.75
15.20 ± 
6.98
08.72 ± 
1.25
Insulin resistance
1.19 ± 
0.12
1.32 ± 
0.34
1.14 ± 
0.43
1.16 ± 
0.97
1.22 ± 
0.25
0.93 ± 
0.56
1.25 ± 
0.74
1.63 ± 
0.96
1.08 ± 
0.39
1.30 ± 
0.84
1.78 ± 
0.76
1.07 ± 
0.57
β-cell function
236.9 ± 
20.12
325 ± 
13.45
169.3 ± 
17.89
219.3 ± 
34.2
258.6 ± 
25.76
90.40 ± 
27.82
270.4 ± 
16.23
402.50 ± 
19.12*
143.5 ± 
26.12
311.3 ± 
35.12
607.5 ± 
45.12*
155.50 ± 
10.23
Insulin action or 
sensitivity (%S)
84.2 ± 
5.61
75.7 ± 
7.43
87.9 ± 
6.78
86.4 ± 
8.92
82.30 ± 
9.23
108.0 ± 
21.78
80.0 ± 
20.11
61.35 ± 
10.94
92.20 ± 
11.45
77.0 ± 
12.56
56.17 ± 
17.34
93.60 ± 
08.12
Diabetic rats
Glucose (m g/dL)
193.83 ± 
10.75
170.50 ± 
08.01
244.33 ± 
10.91
195.00 ± 
15.80
171.00 ± 
16.10
265.00 ± 
22.09
219.83 ± 
13.36
154.10 ± 
09.45
247.00 ± 
15.86
213.66 ± 
09.62
149.66 ± 
13.64
246.83 ± 
12.54
Insulin (µU/mL)
8.8 ± 
4.76
10.84 ± 
6.7
6.8 ± 
3.2
8.6 ± 
6.2
10.56 ± 
2.1
6.2 ± 
1.8
7.5 ± 
4.7
11.89 ± 
9.2
6.43 ± 
8.2
8.12 ± 
7.4
12.13 ± 
9.3
6.4 ± 
9.2
Insulin resistance
1.35 ± 
0.54
1.61 ± 
0.43
1.14 ± 
0.67
1.32 ± 
0.58
1.56 ± 
0.83
1.11 ± 
0.74
1.19 ± 
0.24
1.72 ± 
0.62
1.08 ± 
0.81
1.28 ± 
0.92
1.75 ± 0.36
1.08 ± 
0.56
β-cell function
24.1 ± 
8.65
35.4 ± 
7.54
13.0 ± 
4.65
23.2 ± 
7.89
34.3 ± 
6.89
10.4 ± 
2.87
17.0 ± 
3.43
45.3 ± 
7.51*
12.1 ± 
3.15
18.9 ± 
5.42
49.1 ± 
9.76*
12.2 ± 
1.12
Insulin action or 
sensitivity (%S)
74.1 ± 
11.23
62.2 ± 
8.45
87.6 ± 
12.32
75.6 ± 
9.76
63.9 ± 7
.32
89.9 ± 
13.23
83.7 ± 
12.45
58.2 ± 
9.74
92.3 ± 
17.45
78.1 ± 
18.65
57.2 ± 
12.21
92.5 ± 
9.84
Notes: Data were expressed as mean ± SD (N=6); * significant at P<0.05 compared to metformin control. Abbreviations: SDA - single dose administration; 
MDA- multi dose administration.
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Eisenbarth, 1990). The major factor considered to be 
involved is stress, which is particularly so in the case of 
type-2 diabetes (Lloyd, Smith, Weinger, 2005). Moreover, 
whether it is type 1 or type 2 diabetes, when the disease 
becomes chronic it leads to a further increase in stress due 
to hyperglycemia and the increased oxidation of glucose, 
leading to several comorbid conditions including cardiac 
disorders, retinopathy, nephropathy and neuropathy. 
Hence, the treatment of diabetes should be aimed at 
controlling hyperglycemia along with cardiac disorders, 
such as arrhythmias. Antidiabetic and antiarrhythmic 
drug treatments are given simultaneously to control blood 
glucose and arrhythmias, respectively.
The doses of selected drugs administered to the rats 
and rabbits were calculated, based on human therapeutic 
dose ( TD) and extrapolated to animals, based on body 
surface area using the formula in the rat dose = 0.018 × 
human TD; and the rabbit dose = 0.07 × human TD (Ghosh, 
1984). Such doses were taken as the TD depending on 
their effect, particularly regarding the antidiabetic drugs; 
suitable doses that produced a 30-45% of blood glucose 
reduction were arrived at and these doses were employed 
for the interaction studies.
Disopyramide is an antiarrhythmic drug with 
a sodium channel blockade mechanism, and induces 
hypoglycemia. Hypoglycemia is thought to be due to 
pancreatic β cell over production of insulin because 
sodium channel blockers inhibit sodium ions and increase 
the concentration of intracellular ATP by lowering the 
consumption of ATP. This action inhibits ionic K+ATP and 
causes depolarization of the β cells, followed by activating 
calcium channels, increasing calcium concentration, 
which is followed by an increased release of insulin.
Metformin is a widely used drug in the treatment of 
TABLE IV- Percentage blood glucose reduction after oral administration of metformin 70 mg/1.5 kg body weight, disopyramide 
14 mg/1.5 kg body weight, disopyramide single dose study and multiple dose study in normal rabbits (n=6)
Time (h)
Mean percentage blood glucose reduction ± SD
Metformin Disopyramide Single dose combination Multiple dose combination
1 10.77 ± 01.98 09.70 ± 03.31 12.34 ± 02.31 13.60 ± 01.84*
2 26.22 ± 02.63 17.63 ± 01.90 28.82 ± 02.69 31.16 ± 03.53*
3 31.09 ± 01.54 24.83 ± 02.40 41.14± 03.18*** 43.11 ± 03.52**
4 27.74 ± 04.22 28.16 ± 02.20 38.23± 03.09*** 39.09 ± 04.16**
6 25.32 ± 02.90 21.96 ± 01.90 33.25 ± 03.85** 33.04 ± 02.90**
8 19.38 ± 01.20 17.20 ± 01.40 24.48 ± 02.76** 25.19 ± 04.01*
12 14.13 ± 02.20 12.53 ± 00.80 16.42 ± 03.34 18.21 ± 03.25*
16 8.37 ± 01.89 09.68 ± 01.20 12.36 ± 02.37* 14.07 ± 01.49
20 1.26 ± 00.49 07.46 ± 01.20 07.31 ± 01.60** 09.14 ± 02.61*
24 0.92 ± 00.23 01.25 ± 00.40 05.50 ± 00.93 06.17 ± 01.22
*** Significant at P<0.001; ** Significant at P< 0.01; *Significant at P<0.05 compared to control metformin 2TD.
FIGURE 3 - Serum metformin concentration (ng/mL) vs. time in normal rabbits and in presence of disopyramide (n=6).
K. A. Khan, S. Satyanarayana, K. E. Kumar
Braz. J. Pharm. Sci. 2017;53(4):e00054Page 8 / 10
type-2 diabetes, as well as in type-1 diabetes along with 
insulin, and it is well established that its hypoglycemic 
effect is achieved by increasing glucose transport across 
the cell membrane, particularly in skeletal muscle. It 
has multiple antidiabetic effects, such as the inhibition 
of gluconeogenesis, delay of gastrointestinal absorption 
of glucose, reduction of food intake and prevention of 
body weight gain in obese patients with type-2 diabetes 
and in animal models of obesity (Bailey, Turner, 1996). 
Metformin increases plasma active glucagon, such 
as peptide-1(GLP-1), in obese non-diabetic subjects 
(Mannucci et al., 2001). The above mechanisms might 
also be responsible for its hypoglycemic effect in rats and 
rabbits.
The combination of disopyramide and metformin 
enhanced the hypoglycemic activity; this may be due to 
their added pharmacodynamic activity. Metformin is not 
metabolised by the hepatic microsomal enzyme system 
and is excreted unchanged. Hence, the enhancement 
of metformin action may not be due to the metabolic 
TABLE V - Effect of disopyramide on the activity of metformin in normal rabbits (N=6)
Parameter
Metformin Disopyramide
Disopyramide + metformin 
(SDA)
Disopyramide + metformin 
(MDA)
3rd h 6th h 12th h 3rd h 6th h 12th h 3rd h 6th h 12th h 3rd h 6th h 12th h
Glucose(mg/dL)
71.83 ± 
05.91
77.83 ± 
06.61
89.50 ± 
07.17
79.00 ± 
05.80
82.00 ± 
05.50
91.83 ± 
04.02
60.83 ± 
06.10
69.00 ± 
07.00
86.33 ± 
07.30
58.83 ± 
06.49
69.16 ± 
06.17
84.50 ± 
07.45
Insulin (µU/mL)
10.84 ± 
03.45
09.78 ± 
05.52
8.23 ± 
06.33
09.52 ± 
03.41
09.02 ± 
02.56
7.62 ± 
01.47
15.87 ± 
03.71* 
11.82 ± 
07.65
08.83 ± 
04.43
18.76 ± 
07.58*
12.54 ± 
02.34
09.12 ± 
01.46
Insulin resistance
01.92 ± 
00.80
1.87 ± 
00.60
1.81 ± 
00.10
1.856 ± 
0.24
1.826 ± 
0.32
1.72 ± 
0.45
2.3 8± 
0.27
2.01 ± 
0.47
1.88 ± 
2.71 ± 
0.57
2.14 ± 
0.45
1.90 ± 
0.35
β-cell function
442.44 ± 
21.23
238.5 ± 
32.65
111.97 ± 
10.12
216.36± 
12.7
171.80± 
23.41
95.25 ± 
11.34
2441.5 ± 
85.23*
716.36 ± 
45.74
136.8 9± 
27.12
1563.3 ± 
76.45*
735.29 ± 
45.32
162.85 ± 
13.54
Notes: Data were expressed as mean ± SD (N=6); * significant at P<0.05 compared to metformin control. Abbreviations: SDA - single dose administration; MDA- 
multi dose administration.
TABLE VI - Pharmacokinetic parameters after administration of metformin 70 mg/1.5 kg body weight, disopyramide 14 mg/1.5 kg 
body weight, single dose and metformin, disopyramide multiple dose and metformin in normal rabbits (n=6)
Kinetic parameters Metformin Single dose combination Multiple dose combination
AUC0-24 (ng/mL/h) 14318.75±585.28 14899.67±492.61 15021.17±415.15
AUMC0-24 (ng/mL/h*h) 258983.50±17280.0 272597.60±12649.75 277448.20±8921.80
Kel(h-1) 0.035±00.00 00.34±00.00 00.03±00.00
AUC0-∞ (ng/mL/h) 26046.33±2313.86 27521.08±1520.48 28207.91±1000.40
AUMC0-∞ (ng/mL/h*h) 874116.1±129647.1 941716.10±80069.00 983130.40±44358.00
T1/2 (h) 19.55±01.28 20.05±00.75 20.44±00.22
Ka(h-1) 01.15±00.00 01.15±00.00 01.15±00.00
Clearance(mL/h) 2856.42±336.00 2685.33±123.85 2621.84±196.72
Clearance(mL/h/kg) 1803.41±160.06 1680.78±86.27 1656.02±58.50*
Vdss(mL) 92488.59±6560.02 89407.21±4621.44 89063.05±6502.68
Vdss(mL/kg) 58425.81±1651.52 55905.95±1471.56* 56248.81±1477.73*
Vdarea(mL) 80174.55±5404.59 77699.32±4297.50* 77340.98±5667.54
Vdarea(mLkg) 50652.97±1255.45 48576.90±1253.19* 48844.94±1295.67
MRT(h) 33.40±02.00 34.16±01.06 34.82±00.38
Cmax (ng/mL) 1184.00±35.70 1209.00 ± 17.62 1219.66±17.22
Tmax (h) 03.00±00.00 03.00±00.00 03.00±00.00
*** Significant at P<0.001; ** Significant at P< 0.01; *Significant at P<0.05 compared to control metformin.
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competitive inhibition exerted by disopyramide. 
Furthermore, since there was no change in the time of 
peak or duration of activity, the absorption does not appear 
to be affected. The metformin hypoglycemic response 
(%) exhibited only one peak, indicating that it does not 
enter the biliary excretion and enterohepatic circulation 
systems. Therefore, the increase in hypoglycemic 
response in the presence of disopyramide might be 
due to the combined pharmacodynamic effect. The 
single and multiple dose effects of the antiarrhythmic 
drug on metformin in normal and diabetic rats were 
similar, indicating that it did not affect the metabolism 
of metformin, even when administered longer term. The 
effect of disopyramide on metformin was found to be less 
severe and the combinations need not be considered as 
negative interactions.
The combination of metformin with disopyramide 
produced a blood glucose reduction earlier in rabbits than 
rats. However there was more blood glucose reduction 
in rats compared to rabbits, indicating that the rats were 
more sensitive to hypoglycemic agents than rabbits. The 
hypoglycemic effect of the combination of metformin with 
disopyramide is shown in Tables I, II and III.
The disopyramide and metformin combination 
produced a significant (P<0.05) elevation in insulin 
levels when compared to the metformin control group; 
the elevation was higher in the MDA treated group, as 
shown in Table IV.
In this study we investigated the effect  of 
disopyramide on the activity of metformin with respect 
to glucose, insulin resistance and β cell function using 
HOMA, which is a suitable and validated substitute 
measure (Bonora et al., 2000). In this study, the multiple 
dose effect of disopyramide on metformin activity 
was examined to determine the influence of long term 
treatment with disopyramide, because both are used in 
chronic conditions.
The pharmacodynamics of metformin were 
increased by disopyramide following single and multiple 
dose administration in rats and rabbits, even though 
disopyramide has shown notable alterations in glucose-
insulin homeostasis.
There was a marginal increase in pharmacokinetic 
parameters of metformin with multiple dose treatments 
of disopyramide, such as AUC, AUMC, clearance, 
Vdss, Vdarea and Cmax; and there were no significance 
differences in kinetic parameters between the single 
dose and multiple dose studies. The marginal increase in 
bioavailability cannot be due to improved absorption, since 
the absorption rate and absorption half-life of metformin 
was not altered, as shown in Table V. Metformin protein 
binding is almost negligible (Lee, 1996), whereas 
disopyramide is bound to the extent of 50% to 65% 
(Norpace(R), 1995). Metformin is not metabolised in 
the liver (Lee et al., 1996) so there is no possibility for 
interaction at the metabolism and distribution stages. 
Metformin is excreted unchanged through the kidney 
by the tubular secretion process; and disopyramide (40-
50%) is also excreted by a similar mechanism (Karim 
1975; Ranney et al., 1971) in an unchanged form. 
Therefore, there may be slight possibility of interaction 
at the excretion stage, and the additive pharmacological 
action in improving the secretion of insulin/action 
contributes to the increased pharmacodynamic response 
of metformin. Hence, the interaction appears to be due to a 
pharmacodynamic mechanism and weak pharmacokinetic 
mechanism at the excretion stage.
CONCLUSION
This study validates the drug interaction in two 
dissimilar species, which indicates more probability of its 
occurrence in humans.
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